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INTRODUCTION
Type 2 diabetes is the most common metabolic disease worldwide,1 
and its incidence has increased dramatically in parallel with the 
increased prevalence of obesity.2 Type 2 diabetes is characterized 
by the resistance of target tissues to insulin action.3 Skeletal muscle 
is the major site for glucose disposal after a meal, taking up about 
75% of circulating glucose.4 Therefore, alterations in skeletal muscle 
metabolism can lead to insulin resistance and type 2 diabetes. It has 
been described that type 2 diabetic patients show a reduction in 
oxidation capacity and a decrease in the percentage of oxidative 
type 1 fibers together with lipid accumulation in skeletal muscle.5,6 
Moreover, in humans, there is a clear correlation between triglycer-
ide accumulation in muscle cells (intramyocellular lipids) and insulin 
resistance.7,8
SIRT1, a member of the Sirtuins family, plays a pivotal role in skel-
etal muscle regulation of fatty acid oxidation.9 Sirtuins are a fam-
ily of protein deacetylases and ADP-ribosyltransferases involved 
in different processes such as cellular metabolism, response to 
stress or caloric restriction and lifespan.10,11 In mammals, seven sir-
tuins (SIRT1–7) have been identified.12 SIRT1 has NAD+-dependent 
deacetylase activity and is capable of modulating gene expres-
sion through deacetylation of proteins and transcription factors 
in several key metabolic tissues such as liver, skeletal muscle, and 
white adipose tissue.13 In skeletal muscle, the role of SIRT1 in the 
regulation of lipid metabolism and glucose homeostasis has not 
been fully elucidated yet, but reduced levels of SIRT1 have been 
reported in the skeletal muscle of mice14 and humans15 with insulin 
resistance. In the skeletal muscle of animals treated with SIRT1 acti-
vators, the expression of genes involved in oxidative metabolism is 
up-regulated and mitochondrial function improves, mainly through 
PPARGC1 deacetylation and activation; these changes are associ-
ated with prevention of insulin resistance development.16–18 These 
observations have made SIRT1 a good candidate for the treatment 
of obesity and insulin resistance.
In vivo gene therapy offers the possibility of a one-time treat-
ment with the prospect of lifelong beneficial effects. Adeno-
associated viral (AAV) vector–mediated gene transfer, in particular, 
has shown promising results in several in vivo applications19 driv-
ing multiyear expression of therapeutic transgenes for a variety of 
diseases.20 Moreover, intramuscular administration of AAV vectors is 
a convenient approach to efficiently engineer the skeletal muscle. 
Specifically, AAV vector of serotype 1 (AAV1) is the serotype with 
high tropism for skeletal muscle upon intramuscular administra-
tion21; a single intramuscular injection of AAV1 to mice allows the 
transduction of ~80% of muscle fibers.22
Here, we examined the ability of the skeletal muscle-specific over-
expression of SIRT1 to prevent insulin resistance induced by high fat 
(HF) diet in adult mice, as a potential gene therapy approach for the 
treatment of obesity and type 2 diabetes. We found that AAV vec-
tor-mediated skeletal muscle-specific Sirt1 gene transfer led to the 
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Type 2 diabetes is characterized by triglyceride accumulation and reduced lipid oxidation capacity in skeletal muscle. SIRT1 is a 
key protein in the regulation of lipid oxidation and its expression is reduced in the skeletal muscle of insulin resistant mice. In this 
tissue, Sirt1 up-regulates the expression of genes involved in oxidative metabolism and improves mitochondrial function mainly 
through PPARGC1 deacetylation. Here we examined whether Sirt1 overexpression mediated by adeno-associated viral vectors of 
serotype 1 (AAV1) specifically in skeletal muscle can counteract the development of insulin resistance induced by a high fat diet in 
mice. AAV1-Sirt1-treated mice showed up-regulated expression of key genes related to β-oxidation together with increased levels 
of phosphorylated AMP protein kinase. Moreover, SIRT1 overexpression in skeletal muscle also increased basal phosphorylated 
levels of AKT. However, AAV1-Sirt1 treatment was not enough to prevent high fat diet-induced obesity and insulin resistance. 
Although Sirt1 gene transfer to skeletal muscle induced changes at the muscular level related with lipid and glucose homeostasis, 
our data indicate that overexpression of SIRT1 in skeletal muscle is not enough to improve whole-body insulin resistance and that 
suggests that SIRT1 has to be increased in other metabolic tissues to prevent insulin resistance.
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up-regulation of genes key to β-oxidation and mitochondrial bio-
genesis, and also to increased levels of phosphorylated AMP protein 
kinase (AMPK). Moreover, SIRT1 overexpression in skeletal muscle 
also increased the levels of phosphorylated AKT in basal conditions. 
However, treatment with AAV1-Sirt1 vectors was insufficient to pre-
vent the development of obesity and HF diet-induced whole-body 
insulin resistance.
ReSUlTS
Skeletal muscle Sirt1 gene transfer
AAV1 vectors were used to obtain long-term expression of the Sirt1 
gene in skeletal muscle. Mice received a single total dose of 1 × 1011 
vg/mice of either AAV1-CAG-Null (AAV1-Null) or AAV1-CAG-Sirt1 
(AAV1-Sirt1) distributed between the quadriceps, gastrocnemius, 
and tibialis cranealis muscles of each hindlimb (Figure 1a). Mice 
were analyzed 16 weeks after vector delivery and, as expected, 
SIRT1 protein levels were increased in all muscles injected with 
AAV1-Sirt1, whereas no increase was observed in other metaboli-
cally relevant tissues such as liver and epididymal white adipose tis-
sue (Figure 1b). In agreement with the increased expression of SIRT1 
protein, the acetylated form of p53 (Ac-p53Lys379) -a known target of 
SIRT1 (ref. 23)- was reduced by ~85% in nuclear extracts of quadri-
ceps muscles from mice that received AAV1-Sirt1 vectors (Figure 1c), 
providing evidence of increased SIRT1 activity in skeletal muscle 
after AAV1-Sirt1 injection.
Increased oxidative capacity in skeletal muscle following AAV1-
Sirt1 administration
To determine whether SIRT1 overexpression increased the skel-
etal muscle oxidative capacity under obesogenic conditions, mice 
overexpressing SIRT1 were fed a high fat (HF) diet for 15 weeks, 
and the local effects of SIRT1 overexpression on lipid metabolism 
were examined. The expression of the gene encoding for Carnitine 
Palmitoyltransferase 1, muscular isoform (Cpt1b), a key enzyme 
governing the entry of long-chain acyl-CoAs into mitochondria, 
was increased in gastrocnemius muscle (Figure 2a). Moreover, the 
expression of Uncoupling protein 3 (Ucp3), a protein that uncouples 
oxidative phosphorylation and may promote the conversion of 
intracellular fat into heat, was increased in both the gastrocnemius 
and quadriceps muscles of AAV1-Sirt1-treated mice compared 
with AAV1-Null-injected mice (Figure 2a,b). Similarly, expression of 
Pyruvate Dehydrogenase Kinase, isoenzyme 4 (Pdk4), a key inhibitor 
of the pyruvate dehydrogenase complex, was upregulated in gas-
trocnemius and quadriceps muscles from AAV1-Sirt1-treated mice 
(Figure 2a,b). In addition, Peroxisome proliferative activated recep-
tor delta (PPARδ) was slightly upregulated in quadriceps and gas-
trocnemius muscles of AAV1-Sirt1 mice, respectively (Figure 2a,b). 
Despite these changes, which altogether suggested an increase in 
the capacity for fat oxidation of the gastrocnemius and quadriceps 
muscles overexpressing Sirt1, the expression levels of Ppargc1a, a 
master regulator of lipid metabolism and one of the main targets 
of SIRT1,24 remained unchanged (Figure 2a,b). However, the expres-
sion levels of Transcription factor A, mitochondrial (Tfam) and Sirtuin 
3 (Sirt3), known targets of PPARGC1A,25,26 were higher in gastrocne-
mius muscle following AAV1-Sirt1 treatment (Figure 2a). Although 
the mRNA levels of other sirtuins such as Sirtuin 4 and Sirtuin 5 were 
not changed in treated muscles (data not shown), the expression 
levels of Sirtuin 6, a potential target of SIRT1,27 were significantly 
increased or showed a positive tendency in all injected muscles after 
AAV1-Sirt1 treatment (Figure 2a–c). Since the increased expression 
of oxidative genes observed in gastrocnemius and quadriceps may 
reflect a shift in the predominant fiber type in these muscles, the 
expression of myosin isoforms was examined. The gastrocnemius 
and quadriceps muscles from AAV1-Sirt1-treated mice showed a 
trend to express higher levels of the oxidative fiber marker MyHC 
I when compared with AAV1-Null mice, whereas no differences 
were observed in the levels of MyHC IIa, MyHC IIb, and MyHC IIx 
(Figure 2a,b). Furthermore, the content of MYHCI protein was also 
increased in quadriceps and gastrocnemius samples from mice 
that received AAV1-Sirt1 vectors, reaching statistical significance 
in quadriceps muscle (Figure 3a). Although AAV-derived SIRT1 was 
also overexpressed in tibialis muscle, no significant changes were 
observed in the expression of genes involved in lipid oxidation and 
mitochondrial biogenesis in this muscle (Figure 2c). In accordance 
with this observation, the expression of MyHC I remained unchanged 
in the tibialis muscle of AAV1-Sirt1-treated mice (Figure 2c). Thus, 
these results suggest changes after AAV1-Sirt1 delivery in the pat-
tern of fiber type composition, associated with an increase in the 
oxidative capacity, in gastrocnemius and quadriceps but not in tibi-
alis muscles. However, the increased expression of oxidation-related 
genes was not parallel with a decrease in the triglyceride content in 
gastrocnemius and quadriceps of AAV1-Sirt1-treated mice fed a HF 
diet compared with AAV1-Null-injected animals (Figure 3b).
AMPK activation after AAV1-Sirt1 delivery
The activation by phosphorylation of AMPK controls β-oxidation 
activity and the switch toward type 1 fibers. Several reports have 
shown a strong relationship between SIRT1 and AMPK, indicat-
ing that one could activate the other and vice versa.28,29 To analyze 
whether Sirt1 gene transfer to skeletal muscle could induce phos-
phorylation of AMPK, western blot analysis was performed. Mice 
that received AAV1-Sirt1 vectors and were fed a HF diet presented 
higher ratios of phosphorylated AMPK over total AMPK (AMPK-P/
AMPKtot) in comparison with AAV1-Null-injected mice, reaching 
statistical significance in tibialis and quadriceps muscles (Figure 4a). 
These data indicate that Sirt1 gene transfer to skeletal muscle acti-
vates AMPK, which may lead to an increase in the oxidative capacity 
of this tissue.
SIRT1 and AMPK have been both shown to influence insulin sen-
sitivity under either normal or high-fat diet-fed conditions.16,30–32 In 
order to examine whether AAV1-Sirt1 treatment also had effects 
on insulin signaling in skeletal muscle, the ratio between the phos-
phorylated form of AKT (AKT-P) and total AKT was evaluated by 
Western blot in all injected muscles. As shown in Figure 4b, in basal 
conditions, the ratio AKT-P/AKT total was increased in all injected 
muscles, reaching statistical significance in gastrocnemius and tibi-
alis muscles of mice that received AAV1-Sirt1 vectors. These data 
suggest that SIRT1 overexpression in skeletal muscle improves insu-
lin signaling in this tissue.
AAV1-Sirt1-treated mice were not protected against high fat diet-
induced obesity and insulin resistance
Next, we examined whether skeletal muscle SIRT1 overexpression 
protected mice against the development of obesity induced by a 
high fat diet. After 15 weeks of HF diet feeding, both AAV1-Null and 
AAV1-Sirt1-treated mice increased their body weight by about 70% 
(Figure 5a) and no differences were observed in the food intake 
between groups (data not shown). In addition, the epididymal 
white adipose tissue and brown adipose tissue fat pads weighted 
the same in mice that received either AAV1-Sirt1 or AAV1-Null 
3
Sirt1 increases oxidative capacity in muscle
L Vilà et al.
Molecular Therapy — Methods & Clinical Development (2016) 16072Official journal of the American Society of Gene & Cell Therapy
vectors (Figure 5b,c). Hematoxylin-eosin staining also showed 
similar adipocyte size in epididymal white adipose tissues from 
both groups of animals and no differences were observed in the 
degree of lipid accumulation in the brown adipose tissue of AAV1- 
Sirt1-treated mice (Figure 5d). In addition, HF diet-induced fat 
deposition in the liver was very similar in both groups of mice 
(Figure 5d,e). Moreover, the serum lipid profile, which included tri-
glycerides, total cholesterol, HDL-cholesterol, LDL-cholesterol, and 
free fatty acids was similar in both groups of AAV-injected HF diet-
fed mice (data not shown).
Finally, the effects of muscle SIRT1 overexpression on whole-body 
insulin sensitivity were also analyzed. The intraperitoneal insulin-
tolerance test showed that the response to insulin was blunted to a 
similar extent in AAV1-Null-injected mice than in AAV1-Sirt1-treated 
mice, indicating that SIRT1 overexpression in skeletal muscle did 
not prevent the development of systemic insulin resistance under 
a HF diet (Figure 5f ). Furthermore, glucose and insulin levels in fed 
conditions were similar in AAV1-Sirt1 and AAV1-Null-injected mice 
(Figure 5g). All these results indicate that SIRT1 overexpression in 
skeletal muscle does not prevent the development of obesity and 
insulin resistance induced by high fat feeding.
DISCUSSION
Although several studies have demonstrated that whole-body acti-
vation of SIRT1 has beneficial effects on lipid and glucose metabo-
lism, the tissue-specific actions of SIRT1 remain to be elucidated.16–18 
To address this type of scientific question, the most common 
strategy is to generate transgenic animal models with tissue-specific 
expression of the protein of interest. In these cases, however, the 
phenotype observed in adult animals may not be the direct result 
of the effects of transgene expression in the adult tissue but the 
consequence of its expression during embryonic development.33 In 
our study, we took advantage of AAV1, a vector serotype with high 
tropism for skeletal muscle upon intramuscular administration, to 
induce overexpression of SIRT1 in fibers of several muscles, allowing 
long-term expression of the transgene only in adulthood.
We show in HF diet-fed mice that SIRT1 overexpression in skel-
etal muscle leads to increased expression of genes related to lipid 
oxidation in gastrocnemius and quadriceps. AAV1-Sirt1-treated 
mice showed up-regulated levels of Pdk4, an enzyme that coordi-
nates the shift from glucose metabolism toward fatty acid oxida-
tion,9 and Cpt1b, the enzyme controlling the entrance of fatty acids 
into the mitochondria to be oxidized.34 These genes were also up-
regulated in skeletal muscle of mice treated with the SIRT1 activa-
tor SRT1720.16 Mice that received AAV1-Sirt1 vectors also showed 
increased expression of Ucp3 in all treated muscles, whose expres-
sion improves mitochondrial function, reducing the possibility of 
lipid-induced oxidative damage.2 Accordingly, the SIRT1 activator 
resveratrol also induced higher levels of Ucp3 transcripts in the gas-
trocnemius muscle of HF diet fed mice.17 In contrast, no changes 
were observed in our study in the mRNA levels of Ppargc1a, one of 
the main target genes of SIRT1. However, AAV1-Sirt1-treated mice 
showed increased expression levels of two of PPARG1AC target 
genes in the gastrocnemius muscle, Tfam and Sirt3,25,26 and these 
Figure 1  Intramuscular administration of AAV1-CAG-Sirt1 vectors led to SIRT1 overexpression specifically in skeletal muscle. (a) Schematic 
representation of the AAV genome encoding the codon-optimized murine Sirt1 sequence under the control of the CAG promoter. ITR, inverted terminal 
repeat. (b) Representative Western blots and their corresponding quantifications illustrating the content of SIRT1 in quadriceps, gastrocnemius, and 
tibialis muscles, in epididymal white adipose tissue (eWAT) and in liver of mice receiving AAV1-CAG-Null (AAV1-Null) or AAV1-CAG-Sirt1 vectors (AAV1-
Sirt1) at a dose of 1.6 × 1010 vg per muscle and fed a high fat (HF) diet for 15 weeks following vector delivery. (c) Representative Western blots and 
corresponding quantifications of the levels of total p53 protein (p53tot) and acetylated p53 (Ac-p53) in skeletal muscle of AAV1-Null and AAV8-Sirt1 
mice. a. u., arbitrary units. Data represent the mean ± SEM of at least four animals per group. *P < 0.05 and ***P < 0.001 versus AAV1-Null. AAV1, adeno-
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increases suggest that PPARG1A activity was higher after AAV1-Sirt1 
delivery, at least in gastrocnemius muscle. Moreover, AAV1-Sirt1-
treated mice also presented increased mRNA levels of Sirt6, a poten-
tial target of SIRT1,27 in all SIRT1 overexpressing muscles. Although 
the role of Sirt6 in skeletal muscle metabolism remains uncertain, it 
seems to mediate the increase of fatty acid oxidation through Hif1a 
suppression.35 In agreement with the observation of reduced lev-
els of the acetylated form of p53, the expression data indicate that 
the Sirt1 transgene is active in skeletal muscle of AAV1-Sirt1-treated 
mice, and suggest that lipid oxidation and mitochondrial biogene-
sis might be augmented in gastrocnemius and quadriceps muscles 
of AAV1-Sirt1 mice. The increase in oxidative genes was accompa-
nied by up-regulation, at mRNA and protein levels of MYHC I expres-
sion, a marker of the fiber type with highest oxidative capacity. A 
similar observation has been made in a mouse model of Duchenne 
Muscular Dystrophy which overexpresses a gain-of-function ver-
sion of SIRT1 specifically in the muscle from birth36 and by admin-
istration of the activator SRT1720,16 suggesting that SIRT1 overex-
pression or activation induces fiber remodeling toward an oxidative 
phenotype. Ppard, Sirt3, and Cpt1b overexpression may also induce 
shift toward the oxidative fiber type,5,37,38 and their up-regulation 
in AAV1-Sirt1-treated mice may have contributed to the shift from 
type 2 to type 1 fibers and also to a more oxidative phenotype in 
gastrocnemius and quadriceps muscles of these mice.
The changes related to oxidative metabolism observed in the 
gastrocnemius and quadriceps muscles of AAV1-Sirt1-treated mice 
were, however, not detected in tibialis, despite the fact that this 
muscle also overexpressed SIRT1. Gastrocnemius, quadriceps and 
tibialis are all considered glycolytic muscles, but they differ in their 
fiber composition. It has been shown that the gastrocnemius and 
quadriceps muscles predominantly contain type 2 glycolytic fibers, 
but also a small proportion of type 1 oxidative fibers, whereas the 
tibialis muscle does not contain type 1 oxidative fibers.39,40 The pres-
ence of some type 1 fibers in gastrocnemius and quadriceps mus-
cles may confer more plasticity to these muscles allowing the shift 
from a glycolytic to a more oxidative phenotype.
SIRT1 and AMPK act as sensors of the cellular energy status and 
coordinately regulate the switch from glucose to fatty acid oxida-
tion in the mitochondria.11,41 We observed increased levels of AMPK 
phosphorylation in all injected muscles following AAV1-Sirt1 treat-
ment. As SIRT1 has been described as an AMPK activator,29 these 
data reinforce the idea that SIRT1 is active in our animal model. 
Figure 2 AAV1-Sirt1-treated mice showed increased expression of oxidative genes in skeletal muscle. (a,b,c) The expression levels of Peroxisome 
proliferative activated receptor, gamma, coactivator 1 alpha (Ppargc1a), Transcription factor A mitochondrial (Tfam), Peroxisome proliferative activated 
receptor alpha (Ppara), Peroxisome proliferative activated receptor delta (Ppard), Carnitine palmitoyltransferase 1, muscular isoform (Cpt1b), Pyruvate 
Dehydrogenase Kinase, isoenzyme 4 (Pdk4), Uncoupling protein 3 (Ucp3), Sirtuin 3 (Sirt3), Sirtuin 6 (Sirt6), and markers of fiber types MyHCI, MyHCIIa, 
MyHCIIb, and MyHCIIx were quantified by RT-qPCR in gastrocnemius a, quadriceps b, and tibialis c of AAV1-Null and AAV1-Sirt1-injected mice. Data 
represent the mean ± SEM of at least four animals per group. *P < 0.05 and **P < 0.01 versus AAV1-Null. AAV1, adeno-associated viral vectors of serotype 1; 
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Moreover, although AMPK has been associated with the shift from 
muscle glycolytic fiber type 2 to oxidative type 1,41,42 in our study 
the effect of SIRT1 on AMPK activation might be a direct effect, 
independent of the shift in the fiber type pattern, at least in tibialis 
muscle. In addition, as AMPK activation stimulates lipid oxidation by 
reducing malonyl-CoA levels, an inhibitor of m-Cpt1,43 these results 
reinforce the role of SIRT1 overexpression in activating oxidative 
capacity in skeletal muscle.
Therapeutic strategies aiming at increasing lipid oxidation and 
mitochondrial function in skeletal muscle may be of particular 
interest for the treatment of type 2 diabetes and obesity, since lipid 
accumulation in nonadipose tissues is effectively involved in the 
development of insulin resistance.4 Moreover, skeletal muscle has 
key advantages as a target tissue for AAV-mediated gene transfer. 
Muscle is easily accessible by noninvasive procedures and intramus-
cular vector delivery leads to minimal systemic distribution of the 
vector.22 SIRT1, which can control lipid oxidation, glucose metabo-
lism, and mitochondrial function may thus be a good candidate in a 
gene therapy approach for diabetes treatment.10,11
Although several studies have demonstrated that whole-body 
activation of SIRT1 has beneficial effects on lipid and glucose metab-
olism, controversial results have been reported on the tissue-spe-
cific actions of SIRT1, in particular regarding insulin  sensitivity.16–18 
It has been demonstrated in transgenic mice that overexpression of 
SIRT1 specifically in skeletal muscle does not improve insulin sen-
sitivity when animals are fed either chow diet44 or high fat diet.45 
However, previous observations in muscular cells3,46 showed that 
SIRT1 overexpression enhances insulin-induced AKT phosphory-
lation. Consistent with this latter observation, in our model, insu-
lin signaling was improved in the skeletal muscle after AAV1-Sirt1 
treatment, as indicated by the increase in the ratio AKT-P/AKTtotal; 
we did not observe, however, improvement in whole-body insulin 
sensitivity. In addition, the fact that in our mice, the increased levels 
of AKT-P were observed in both gastrocnemius and tibialis muscles 
Figure 3 SIRT1 overexpression led to higher protein levels of oxidative 
fyber type. (a) Representative Western blots and corresponding 
quantifications of the MYHCI content in quadriceps and gastrocnemius 
muscles of AAV1-Null and AAV1-Sirt1-treated mice. (b) Triglyceride 
content in the gastrocnemius and quadriceps. All analyses were 
performed after 15 weeks of HF diet feeding. Data represent the mean ± 
SEM of at least three a or four b animals per group. *P < 0.05 versus AAV1-
Null. AAV1, adeno-associated viral vectors of serotype 1; HF, high fat; SEM, 
standard error of the mean.
a
b
Figure 4 Sirt1 gene transfer to skeletal muscle led to AMPK and AKT activation. (a) Representative Western blots and corresponding quantifications 
of the total AMP protein kinase (AMPKtot) and phosphorylated AMPK (AMPK-P) content in gastrocnemius, tibialis and quadriceps muscles of AAV1-
Null and AAV1-Sirt1-treated mice. (b) Representative Western blots and corresponding quantifications of the content of total AKT (AKTtot) and 
phosphorylated AKT (AKT-P) in gastrocnemius, tibialis, and quadriceps muscles of AAV1-Null and AAV1-Sirt1-treated mice. Tubulin was used as a loading 
control. a.u., arbitrary units. All analyses were performed after 15 weeks of HF diet feeding. Data represent the mean ± SEM of at least four animals per 
group. *P < 0.05 versus AAV1-Null. AAV1, adeno-associated viral vectors of serotype 1; HF, high fat; SEM, standard error of the mean.
a b
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indicates that AKT activation might be independent of the shift in 
fiber type and might be the result of a direct effect of SIRT1 over-
expression, possibly mediated by AMPK activation as other authors 
have reported.31
The amelioration observed in insulin signaling, however, was not 
able to induce positive systemic effects, which is in agreement with 
what has been observed in HF diet fed transgenic mice overexpress-
ing SIRT1 specifically in skeletal muscle.45 Altogether, these results 
and the fact that the knockdown of SIRT1 activity in skeletal muscle 
did not impair in vivo insulin-stimulated AKT-phosphorylation and 
glucose uptake,47 question the role of SIRT1 in skeletal muscle in the 
control of whole-body insulin sensitivity.
Our study also clearly demonstrates that SIRT1 overexpression 
only in skeletal muscle, despite inducing the expected metabolic 
changes, is not sufficient to improve insulin sensitivity, and that 
SIRT1 activation or overexpression in other metabolic tissues, such 
as liver or white and brown adipose tissue may be necessary to 
ameliorate whole-body insulin sensitivity.16,30,48 In this regard, sys-
temic delivery of SIRT1-expressing vectors could be considered an 
alternative. However, thinking from a translational point of view, the 
treatment of insulin resistance with a vector that mediated whole-
body SIRT1 expression would not be the strategy of choice because 
of the possible deleterious effects that SIRT1 overexpression could 
have in certain organs, such as those described in heart49,50 and 
brain.51–53 On the other hand, our group has previously shown that 
AAV8-mediated liver specific SIRT1 overexpression in adult mice pre-
vents the development of fatty liver and insulin resistance induced 
by a high carbohydrate diet.54 Thus, this work demonstrates that 
Figure 5 AAV-Sirt1 treatment did not counteract the development of obesity and insulin resistance after a HF diet. (a) Body weight gain of AAV1-Null 
and AAV1-Sirt1-treated mice fed with a HF for 15 weeks. (b,c) Weight of the epididymal white adipose tissue (eWAT) b and brown adipose tissue (BAT) c 
fat pads. (d) Representative sections of eWAT, BAT and liver stained with hematoxylin-eosin. Original magnification ×100. (e) Liver weight and hepatic 
triglyceride content. (f) Insulin sensitivity was determined after an intraperitoneal injection of insulin (0.75 units/kg body weight). Results are calculated 
as the percentage of initial blood glucose levels. (g) Blood glucose and insulin levels in fed conditions. All analyses were performed after 15 weeks of HF 
diet feeding. Data represent the mean ± SEM of at least 10 a, f, g or 4 b-e animals per group. AAV1, adeno-associated viral vectors of serotype 1; AAV, 
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targeting skeletal muscle to overexpress SIRT1 is not a valid thera-
peutic option and that hepatic-specific Sirt1 gene transfer would 
be the strategy of choice for the treatment of type 2 diabetes. Our 
study underscores the challenge that developing gene therapies for 
complex metabolic diseases represents.
MATeRIAlS AND MeTHODS
Animals
Three-month-old C57Bl/6 male mice were obtained from Harlan labora-
tories (Teklad, Madison, WI). Mice were kept in a specific pathogen-free 
facility (SER-CBATEG) and maintained under a light-dark cycle of 12 hours. 
Mice were fed ad libitum with a high fat diet (HF) (D12451, Research Diets, 
New Brunswick, NJ) for 15 weeks. The HF diet contained 45% of calories as 
fat. Animals were sacrificed under anesthesia and tissues were harvested 
and snap frozen or fixed in formalin. Animal care and experimental pro-
cedures were approved by the Ethics Committee in Animal and Human 
Experimentation of the Universitat Autònoma de Barcelona (UAB).
Recombinant AAV1 vector administration
AAV1 vectors encoding a codon-optimized murine Sirt1 sequence under the 
control of the ubiquitous CAG promoter (containing the chicken β-actin pro-
moter and cytomegalovirus enhancer) (AAV1-CAG-Sirt1) were generated in 
our laboratory by triple transfection of human embryonic kidney 293 cells 
and purified using an optimized cesium chloride gradient-based purification 
protocol.55,56 A noncoding plasmid carrying the CAG promoter was used to 
produce null particles (AAV1-CAG-Null). Vectors were administered by intra-
muscular injection at a dose of 1 × 1011 vg/mice in a total volume of 180 μl 
divided into six injection sites distributed in the quadriceps, gastrocnemius, 
and tibialis cranealis of each hindlimb (1.6 × 1010 vgs per muscle). One week 
later, animals began feeding a HF diet until their sacrifice (16 weeks postin-
jection of vector).
Gene expression analysis
For quantitative real-time polymerase chain reaction analysis, total RNA 
was extracted from different muscles using Tripure isolation reagent 
(Roche Molecular Biochemicals, Mannheim, Germany) and Rneasy Mini 
Kit (Qiagen, Hilden, Germany). Total RNA (1 μg) was retrotranscribed using 
the Transcriptor First Strand cDNA Synthesis Kit (Roche). Real-time poly-
merase chain reaction was performed in a LightCycler 480 II (Roche) using 
LightCycler 480 SyBR Green I Master Mix (Roche). Primer sequences are 
described in Table 1.
Western blot analysis
For total protein extracts, tissues were homogenized in protein lysis buffer 
and centrifuged at 15,000g for 15 minutes at 4ºC. Nuclear extracts were iso-
lated as previously described.57 Proteins were separated by 8% or 10% wt/
vol sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), 
transferred to polyvinylidenedifluoride (PVDF) membranes and probed 
overnight at 4°C. The primary antibodies used were: Anti-Sirt1 (07-131, 
Millipore, Billerica, MA), Anti-AMPK (2532, Cell Signaling, Danvers, MA), Anti-
phospho-AMPK-Thr172 (2531, Cell Signaling), Anti-AKT (9272, Cell Signaling), 
Anti-phospho-AKT-Ser473 (9271, Cell Signaling), Anti-Acetyl-p53-Lys379 (2570, 
Cell Signaling), Anti-Myosin Skeletal Slow (M8421, Sigma-Aldrich, St. Louis, 
MO), Anti-p53 (2524, Cell Signaling) and Anti-α-tubulin (ab4074, Abcam, 
Cambridge, UK). Detection was performed using the corresponding horse-
radish peroxidase-labeled secondary antibodies and western blotting 
detection reagent (ECL Plus; Amersham, Freiburg, Germany).
Immunohistochemical analysis
Tissues were fixed for 24 hours in formalin, embedded in paraffin and sec-
tioned. For histological analysis, sections were deparaffinized and stained 
with hematoxylin/eosin.
Insulin tolerance test
Insulin tolerance test was performed as previously described.58 Briefly, mice 
were given an intraperitoneal injection of insulin and glucose concentra-
tion was determined in blood samples at the indicated time points using a 
Glucometer Elite analyzer (Bayer, Leverkusen, Germany).
Metabolite and hormone assays
Liver and gastrocnemius triglyceride content was determined by extract-
ing total lipids from the tissues with chloroform-methanol (2:1 vol/vol) 
as described by Carr et al.59 Serum triglycerides, total cholesterol, LDL-
cholesterol, and HDL-cholesterol were quantified spectrophotometrically 
using enzymatic assays kit (Horiba-ABX, Montpellier, France). Serum FFAs 
were measured by the acyl-CoA synthase and acyl-CoA oxidase method 
(Wako Chemicals GmbH, Neuss, Germany). All biochemical parameters were 
determined using a Pentra 400 Analyzer (Horiba-ABX). Glucose was deter-
mined using a Glucometer Elite analyzer (Bayer) and insulin levels were mea-
sured using the Rat Insulin ELISA Kit (Crystal Chemical, Chicago, IL).


































qPCR, quantitative polymerase chain reaction.
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Statistical analysis
All values are expressed as the mean ± SEM (standard error of the mean). 
Differences between groups were compared by Student’s t-test. Statistical 
significance was considered if P < 0.05.
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